Medical management of ascites

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 8, 2011, Pages 1269-1283

  Leung, Wesley ^a   Wong, Florence ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

albumin; ascites; cirrhosis; diuretics; renal impairment; spontaneous bacterial peritonitis; vaptans; vasoconstrictors; vasodilatation

Indexed keywords

ALBUMIN; AMILORIDE; ANTIVIRUS AGENT; CANRENOATE POTASSIUM; CEFTRIAXONE; CIPROFLOXACIN; CONIVAPTAN; COTRIMOXAZOLE; CREATININE; DIURETIC AGENT; FUROSEMIDE; MIDODRINE; MOZAVAPTAN; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; PEPTIDE HORMONE ANTAGONIST; RENIN; SATAVAPTAN; SPIRONOLACTONE; SULFAMETHOXAZOLE; TERLIPRESSIN; TOLVAPTAN; VASOCONSTRICTOR AGENT;

ARTERIAL PRESSURE; ASCITES; BACTERIAL PERITONITIS; BED REST; CREATININE BLOOD LEVEL; DIET RESTRICTION; DRUG DOSE INCREASE; ELECTROLYTE BALANCE; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HEPATITIS B; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICAL LITERATURE; NEPHROTOXICITY; NORADRENALIN BLOOD LEVEL; PATHOPHYSIOLOGY; PATIENT MONITORING; PROTEIN CONTENT; REVIEW; SINGLE DRUG DOSE; SODIUM RESTRICTION; SODIUM URINE LEVEL; SPONTANEOUS BACTERIAL PERITONITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING;

ASCITES; BACTERIAL INFECTIONS; HUMANS; LIVER CIRRHOSIS; PERITONITIS; SURVIVAL RATE;

EID: 79955855736     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.549126     Document Type: Review

References (100)

1. Runyon BA, Montano AA, Akriviadis EA, et al.The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites.Ann Intern Med 1992;117:215-20
2. Gines P, Quintero E, Arroyo V, et al.Compensated cirrhosis: Natural history and prognostic factors.Hepatology 1987;7:122-8 (Pubitemid 17019862)
3. Planas R, Montoliu S, Balleste B, et al.Natural history of patients hospitalized for management of cirrhotic ascites.Clin Gastroenterol Hepatol 2006;4:1385-94
4. Runyon BA.Management of adult patients with ascites due to cirrhosis: an update.Hepatology 2009;49:2087-107
5. Moore KP, Wong F, Gines P, et al.The management of ascites in cirrhosis: report in the consensus conference of the International Ascites Club.Hepatology 2003;38:258-66 (Pubitemid 36775818)
6. Van Landeghem L, Laleman W, Vander Elst I, et al.Carbon monoxide produced by intrasinusoidally located haem-oxygenase-1 regulates the vascular tone in cirrhotic rat liver.Liver Int 2009;29:650-60
7. Blendis L, Wong F.The hyperdynamic circulation in cirrhosis: an overview.Pharmacol Ther 2001;89:221-31 (Pubitemid 32539409)
8. Colle I, Geerts AM, Van Steenkiste C, et al.Hemodynamic changes in splanchnic blood vessels in portal hypertension.Anat Rec 2008;291:699-713
9. Cazzaniga M, Salerno F, Visentin S, et al.Increased flow-mediated vasodilation in cirrhotic patients with ascites: relationship with renal resistive index.Liver Int 2008;28:1396-401
10. Bernadich C, Bandi JC, Piera C, et al.Circulatory effects of graded diversion of portal blood flow to the systemic circulation in rats: role of nitric oxide.Hepatology 1997;26:262-7 (Pubitemid 27328299)
11. Bosch J, Pizcueta MP, Fernandez M, et al.Hepatic, splanchnic and systemic haemodynamic abnormalities in portal hypertension.Baillieres Clin Gastroenterol 1992;6:425-36
12. Møller S, Henriksen JH, Bendtsen F.Ascites, pathogenesis and therapeutic principles.Scand J Gastro 2009;44:902-11
13. Wong F, Pantea L, Sniderman K.Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.Hepatology 2004;40:55-64 (Pubitemid 38868923)
14. Jalan R, Forrest EH, Redhead DN, et al.Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997;40:664-70 (Pubitemid 27278337)
15. Lang F, Tschernko E, Schulze E, et al.Hepatorenal reflex regulating kidney function.Hepatology 1991;14:590-4
16. Stadlbauer V, Wright GA, Banaji M, et al.Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis.Gastroenterology 2008;134:111-19
17. Wensing G, Lotterer E, Link I, et al.Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.Hepatology 1997;26:1149-55 (Pubitemid 27509296)
18. Said A, Williams J, Holden J, et al.The prevalence of alcohol-induced liver disease and hepatitis C and their interaction in a tertiary care setting.Clin Gastroenterol Hepatol 2004;2:928-34 (Pubitemid 39335800)
19. Reynolds TB, Geller HM, Kuzma OT, et al.Spontaneous decrease in portal pressure with clinical improvement in cirrhosis.N Engl J Med 1960;263:734-9
20. Runyon BA.Historical aspects of treatment of patients with cirrhosis and ascites.Semin Liver Dis 1997;17:163-73 (Pubitemid 27388055)
21. Villeneuve JP, Condreay LD, Willems B, et al.Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.Hepatology 2000;31:207-10 (Pubitemid 30033708)
22. Malekzadeh R, Mohamadnejad M, Rakhshani N, et al.Reversibility of cirrhosis in chronic hepatitis B.Clin Gastroenterol Hepatol 2004;2:344-7 (Pubitemid 38447201)
23. Garcia-Pagan JC, Salmeron JM, Feu F, et al.Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis.Hepatology 1994;19:1095-9 (Pubitemid 24134230)
24. Runyon BA, Antillon MR, McHutchison JG.Diuresis increases ascitic fluid opsonic activity in patients who survive spontaneous bacterial peritonitis.J Hepatol 1992;14:249-52
25. Gauthier A, Levy VG, Quinton A, et al.Salt or no salt in the treatment of cirrhotic ascites: a randomised study.Gut 1986;27:705-9 (Pubitemid 16085558)
26. Angeli P, Wong F, Watson H, et al.Hyponatremia in cirrhosis: results of a patient population survey.Hepatology 2006;44:1535-42 (Pubitemid 44953659)
27. European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.J Hepatol 2010;53:397-417
28. Boyer TD, Reynolds TB.Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979;77:215-22 (Pubitemid 9206030)
29. Clària J Kent JD, López-Parra M, et al.Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.Hepatology 2005; 41 579-87 (Pubitemid 40289506)
30. Pariente EA, Bataille C, Bercoff E, et al.Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites.Gastroenterology 1985;88:1255-9 (Pubitemid 15087631)
31. Gentilini P, Romanelli RG, La Villla G, et al.Effects of low-dose captopril on renal haemodynamics and function in patients with cirrhosis of the liver.Gastroenterology 1993;104:588-94 (Pubitemid 23033435)
32. Tandon P, Abraldes JG, Berzigotti A, et al.Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis.J Hepatol 2010;53:273-82
33. Albillos A, Lledo JL, Rossi I, et al.Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function.Gastroenterology 1995;109:1257-65
34. Cabrera J, Arroyo V, Ballesta AM, et al.Aminoglycoside nephrotoxicity in cirrhosis.Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage.Gastroenterology 1982;82:97-105 (Pubitemid 12183309)
35. Haupel H, Bynum GD, Zamora E, et al.Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis.Am J Gastroenterol 2001;96:2206-10 (Pubitemid 32660919)
36. Guevara M, Fernandez-Esparrach G, Alessandria C, et al.Effects of contrast media on renal function in patients with cirrhosis: a prospective study.Hepatology 2004;40:646-51 (Pubitemid 39265586)
37. Bernardi M, Laffi G, Salvagnini M, et al.Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content.Liver 1993;13:156-62 (Pubitemid 23228712)
38. Sungaila I, Bartle WR, Walker SE, et al.Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites.Gastroenterology 1992;102:1680-5
39. Laffi G, La Villa G, Carloni V, et al.Loop diuretic therapy in liver cirrhosis with ascites.J Cardiovas Pharmacol 1993;22(Suppl 3):S51-58 (Pubitemid 23318423)
40. Angeli P, Della Pria M, De Bei E, et al.Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites.Hepatology 1994;19:72-9 (Pubitemid 24020474)
41. Bolondi L, Piscaglia A, Gatta A, et al.; DOC (Decrease Of Complications in cirrhosis) Study Group.Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis.Clin Gastroenterol Hepatol 2006;4:1395-1402 (Pubitemid 44716736)
42. Fogel MR, Sawhney VK, Neal EA, et al.Diuresis in the ascitic patient: A randomized controlled trial of three regimens.J Clin Gastroenterol 1981;3(Suppl 1):73-80 (Pubitemid 12181864)
43. Santos J, Planas R, Pardo A, et al.Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis.A randomized comparative study of efficacy and safety.J Hepatol 2003;39:187-92 (Pubitemid 36920553)
44. Perez-Ayuso RM, Arroyo V, Planas R, et al.Randomized comparative study of efficacy of furosemide vs spironolactone in nonazotemic cirrhosis with ascites: relationship between the diuretic response and the activity of the renin-aldosterone system.Gastroenterology 1983;84:961-8 (Pubitemid 13119910)
45. Pinzani M, Daskalopoulos G, Laffi G, et al.Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance.Gastroenterology 1987;92:294-8 (Pubitemid 17231706)
46. Licata G, Tuttolomondo A, Licata A, et al.Clinical trial: high-dose furosemide plus small-volume hypertonic saline solutions vs.repeated paracentesis as treatment of refractory ascites.Aliment Pharmacol Ther 2009;30:227-35
47. Angeli P, Fasolato S, Mazza E, et al.Combined versus sequential diuretics treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.Gut 2010;59:98-104
48. Bernardi M.Optimum use of diuretics in managing ascites in patients with cirrhosis.Gut 2010;59:10-11
49. Shear L, Ching S, Gabuzda GJ.Compartmentalization of ascites and edema in patients with hepatic cirrhosis.N Engl J Med 1970;282:1391-6
50. Runyon BA.Treatment of patients with cirrhosis and ascites.Semin Liver Dis 1997;17:249-60 (Pubitemid 27388062)
51. Caregaro L, Menon F, Angeli P, et al.Limitation of serum creatinine level and creatinine clearance as filtration markers in cirrhosis.Arch Intern Med 1994;154:201-5 (Pubitemid 24032194)
52. Pinto-Marques P, Vieira A.Urinary sodium/potassium ratio on random sample as a useful tool to assess diuretic-induced natriuresis on chronic liver disease-associated ascites.Am J Gastroenterol 2007;102:212-13 (Pubitemid 46072079)
53. Bianchi S, Bigazzi R, Campese VM.Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.Kidney Int 2006;70:2116-23 (Pubitemid 44871374)
54. Wall SM.Mechanisms of NH4+ and NH3 transport during hypokalemia.Acta Physiol Scand 2003;179:325-30
55. Gines P, Guevara M.Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.Hepatology 2008;48:1002-10
56. Kale RA, Gupta RK, Saraswat VA, et al.Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy.Hepatology 2006;43:698-706
57. Restuccia T, Gomez-Anson B, Guevara M, et al.Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis.Hepatology 2004;39:1613-22 (Pubitemid 38702662)
58. Gines P, Cardenas A.The management of ascites and hyponatremia in cirrhosis.Semin Liver Dis 2008;28:43-58 (Pubitemid 351326532)
59. Lee FY, Lee SD, Tsai YT, et al.A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps.J Hepatol 1991;12:236-40
60. Angeli P, Albino G, Carraro P, et al.Cirrhosis and muscle cramps: evidence of a causal relationship.Hepatology 1996;23:264-73 (Pubitemid 26045943)
61. Schrier RW, Arroyo V, Bernardi M, et al.Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.Hepatology 1988;8:1151-7
62. Wong F.The role of albumin in the management of chronic liver disease.Nat Clin Pract Gastroenterol Hepatol 2007;4:43-51 (Pubitemid 46055959)
63. Brinch K, Moller S, Bendtsen F, et al.Plasma volume expansion by albumin in cirrhosis.Relation to blood volume distribution, arterial compliance and severity of disease.J Hepatol 2003;39:24-31 (Pubitemid 36724104)
64. Gentilini P, Casini-Raggi V, Di Fiore G, et al.Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized controlled trial.J Hepatol 1999;30:639-45 (Pubitemid 29151905)
65. Romanelli RG, La Villa G, Barletta G, et al.Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.World J Gastroenterol 2006;12:1403-7
66. Cardenas A, Arroyo V.Management of ascites and hydrothorax.Best Pract Res Clin Gastroenterol 2007;21:55-75
67. Angeli P, Volpin R, Piovan D, et al.Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.Hepatology 1998;28:937-43 (Pubitemid 28450253)
68. Kalambokis G, Fotopoulos A, Economou M, et al.Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.J Hepatol 2007;46:213-21 (Pubitemid 44959158)
69. Misra VL, Vuppalanchi R, Jones D, et al.The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites.Aliment Pharmacol Ther 2010;32:1044-50
70. Kalambokis G, Economou M, Fotopoulos A, et al.The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.Am J Gastroenterol 2005;100:879-85
71. Tandon P, Tsuyuki RT, Mitchell L, et al.The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.Liver Int 2009;29:169-74
72. Sanyal AJ, Boyer T, Garcia-Tsao G, et al.A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.Gastroenterology 2008;134:1360-8 (Pubitemid 351615358)
73. Martin-Llahi M, Pepin MN, Guevara M, et al.Terlipressin and albumin vs.albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.Gastroenterology 2008;134:1352-9 (Pubitemid 351626950)
74. Narahara Y, Kanazawa H, Taki Y, et al.Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.J Gastroenterol Hepatol 2009;24:1791-7
75. Krag A, Moller S, Henriksen JH, et al.Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.Hepatology 2007;46:1863-71
76. Kalambokis GN, Pappas K, Baltayiannis G, et al.Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia.Scand J Gastroenterol 2010;45:1509-15
77. Gines P, Wong F, Watson HR, et al.Effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics in patients with cirrhosis without hyponatremia: randomized, double-blind, placebo-controlled study.Aliment Pharmacol Ther 2010;8:834-45
78. Wong F, Gines P, Watson H, et al.Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on recurrence of ascites after large volume paracentesis in patients with cirrhosis.J Hepatol 2010;53:283-9
79. Wong F, Bernardi M, Horsmans Y, et al.Effects of satavaptan, an oral vasopressin V2 receptor antagonist, on management of ascites and morbidity in liver cirrhosis in a long-term, placebo-controlled study.[Abstract].J Hepatol 2009;50(Suppl 1):S42
80. Nevens F, Moreno C, Cools M, et al.Effects of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites.[Abstract].J Hepatol 2009;50(Suppl 1):S76
81. Okita K, Sakaida I, Okada M, et al.A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.J Gastroenterol 2010;45:979-87
82. Wong F, Bernardi M, Balk R, et al.Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club.Gut 2005;54:718-25 (Pubitemid 40559261)
83. Tandon P, Garcia-Tsao G.Bacterial infections, sepsis, and multiorgan failure in cirrhosis.Semin Liver Dis 2008;28:26-42 (Pubitemid 351326531)
84. Novella M, Sola R, Soriano G, et al.Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.Hepatology 1997;25:532-6 (Pubitemid 27106428)
85. Grange JD, Roulot D, Pelletier G, et al.Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial.J Hepatol 1998;29:430-6 (Pubitemid 28396660)
86. Fernandez J, Navasa M, Planas R, et al.Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.Gastroenterology 2007;133:818-24 (Pubitemid 47374144)
87. Terg R, Fassio E, Guevara M, et al.Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study.J Hepatol 2008;48:774-9
88. Deschenes M, Villeneuve JP.Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis.Am J Gastroenterol 1999;94:2193-7 (Pubitemid 29374553)
89. Bernard B, Grange JD, Khac EN, et al.Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis.Hepatology 1999;29:1655-61 (Pubitemid 29247035)
90. Fernandez J, Ruiz del Arbol L, et al.Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.Gastroenterology 2006;131:1049-56 (Pubitemid 44498687)
91. Garcia-Tsao G.Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis.Gastroenterology 2001;120:726-48 (Pubitemid 32171643)
92. Gines P, Rimola A, Planas R, et al.Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial.Hepatology 1990;12:716-24 (Pubitemid 20349256)
93. Soriano G, Guarner C, Teixido M, et al.Selective intestinal decontamination prevents spontaneous bacterial peritonitis.Gastroenterology 1991;100:477-81
94. Rolachon A, Cordier L, Bacq Y, et al.Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial.Hepatology 1995;22:1171-4
95. Singh N, Gayowski T, Yu VL, et al.Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial.Ann Intern Med 1995;122:595-8
96. Follo A, Llovet JM, Navasa M, et al.Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis.Hepatology 1994;20:1495-501 (Pubitemid 24359062)
97. Terra C, Guevara M, Torre A, et al.Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score.Gastroenterology 2005;129:1944-53 (Pubitemid 41772972)
98. Sort P, Navasa M, Arroyo V, et al.Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.N Engl J Med 1999;341:403-9 (Pubitemid 29362513)
99. Fernandez J, Monteagudo J, Bargallo X, et al.A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis.Hepatology 2005;42:627-34 (Pubitemid 41233655)
100. Fernandez J, Navasa M, Garcia-Pagan JC, et al.Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis.J Hepatol 2004;41:384-90 (Pubitemid 39158747)